by John McMillan | Jun 5, 2026 | COVID-19
Dr. Philip McMillan, John McMillan Ask most people about COVID today and you will get a shrug. The word itself has become something nobody wants to hear. Search traffic has fallen off a cliff, much of the scientific community has turned its attention elsewhere, and...
by John McMillan | May 29, 2026 | COVID-19
Dr. Philip McMillan, John McMillan Cancer rates after the pandemic should be falling. In many cases they are not. During the pandemic, a cancer diagnosis made severe or fatal COVID outcomes much more likely. Many patients who would otherwise be filling oncology...
by John McMillan | May 22, 2026 | COVID-19
Bruce Y. Lee, City University of New York and Hannah Dimmick, CUNY Graduate School of Public Health and Public Policy Headlines on long COVID have become much more rare than during the first few years of the COVID-19 pandemic. But that doesn’t...
by John McMillan | May 22, 2026 | COVID-19
Dr. Philip McMillan, John McMillan Something has shifted in the rhythm of public health news. Open any headline aggregator over the past month and the litany reads like the table of contents of a virology textbook. Ebola in the Democratic Republic of Congo. Nipah...
by John McMillan | May 15, 2026 | COVID-19
Dr. Philip McMillan, John McMillan In November of 2023, Barry Young, a senior database administrator at New Zealand’s Te Whatu Ora health department, walked away from his career. He released vaccination and mortality records publicly after sharing them with his...
by John McMillan | May 1, 2026 | COVID-19
Dr. Philip McMillan, John McMillan In April 2026, a randomized controlled trial published as “Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients” by Butler and colleagues finally answered a question that should have been asked four years...
Recent Comments